Paolo Tarantino

TL;DR: The development of margetuximab has relevantly improved the biological understanding of Her2-positive BC, highlighting the implication of patient’s genotype in determining treatment outcomes, as well as the relevance of antibody-dependent cellular cytotoxicity (ADCC) in the context of HER2-blockade.

TL;DR: The present review recapitulates the most promising novel biologic agents being developed for the treatment of ABC, and indicates that multiple drugs are demonstrating activity in late-phase clinical trials for all subtypes.

TL;DR: A review of bispecific antibodies against solid malignancies can be found in this paper, where the authors focus on the state-of-the-art, the design, and the exploitation of bsAbs against solid tumors.

TL;DR: In phase III ImPassion130 trial, the addition of immunotherapy to chemotherapy improved overall survival in metastatic triple-negative breast cancer patients but this benefit was significant only in patients harboring PD-L1-positive tumors, suggesting that stratification according to response biomarkers is needed to achieve consistent responses.

TL;DR: In this article, a real-world, cohort study of patients receiving anticancer treatments and COVID-19 vaccines between 1 February and 25 June 2021 at the Division of New Drugs Development for Innovative Therapies of the European Institute of Oncology was conducted.